Doctors Now Know When to Start CF Drug Kaftrio

Doctors across Europe have been working without clear guidelines on when to start Kaftrio, a groundbreaking cystic fibrosis treatment, for patients whose lungs still function well. Now a survey of 23 CF centers is shedding light on how clinicians make these critical decisions.

Kaftrio, known as Trikafta in the U.S., has transformed lives for people with cystic fibrosis, a genetic condition that causes thick mucus to build up in the lungs and other organs. The drug helps restore the body's ability to balance salt and water, leading to dramatic improvements in lung function.

But here's the challenge: most research has focused on patients with declining lung health. For people whose lungs are still functioning at 90% or better, doctors have been flying blind without official guidance.

The survey found that respiratory symptoms matter most. About 61% of clinicians said breathing issues drive their decision to start treatment, even in patients with stable lung function. Nutritional status came in second at 57%.

Specific red flags prompted nearly universal agreement. When doctors detected Pseudomonas aeruginosa, a dangerous bacteria common in CF patients, 78% supported starting Kaftrio. CT scan abnormalities like airway thickening and mucus plugging convinced 87% of clinicians to prescribe the treatment.

Patient factors also played a role. Being underweight encouraged treatment in 83% of cases, while having CF-related diabetes or chronic sinus inflammation supported the decision for 78% of doctors. Chronic cough and mucus production sealed the deal for 87% of respondents.

Interestingly, some factors made doctors hesitate. Nearly a third held back for patients who were overweight, and 43% showed caution for those with mental health histories. About 22% proceeded more carefully with patients over 50.

Why This Inspires

This research represents something bigger than statistics. Every percentage point reflects real doctors working to give their patients the best possible care, even without an official playbook to follow.

The study's authors noted that "treatment decisions are largely guided by expert opinion and the clinical judgment of individual centers." While that might sound uncertain, it actually reveals dedicated healthcare teams using their experience and expertise to help patients access a therapy that could prevent lung damage before it starts.

The findings will help create evidence-based guidelines that could standardize care across Europe and beyond. That means more patients getting the right treatment at the right time, potentially preventing irreversible lung damage before it begins.

Thousands of people with cystic fibrosis now have hope that earlier treatment could preserve their lung health for decades to come.